Literature DB >> 20399528

Mannose-binding lectin and its associated proteases (MASPs) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation.

Kazue Takahashi1, Wei-Chuan Chang, Minoru Takahashi, Vasile Pavlov, Yumi Ishida, Laura La Bonte, Lei Shi, Teizo Fujita, Gregory L Stahl, Elizabeth M Van Cott.   

Abstract

The first line of host defense is the innate immune system that includes coagulation factors and pattern recognition molecules, one of which is mannose-binding lectin (MBL). Previous studies have demonstrated that MBL deficiency increases susceptibility to infection. Several mechanisms are associated with increased susceptibility to infection, including reduced opsonophagocytic killing and reduced lectin complement pathway activation. In this study, we demonstrate that MBL and MBL-associated serine protease (MASP)-1/3 together mediate coagulation factor-like activities, including thrombin-like activity. MBL and/or MASP-1/3 deficient hosts demonstrate in vivo evidence that MBL and MASP-1/3 are involved with hemostasis following injury. Staphylococcus aureus infected MBL null mice developed disseminated intravascular coagulation (DIC), which was associated with elevated blood IL-6 levels (but not TNF-α and multi-organ inflammatory responses). Infected MBL null mice also develop liver injury. These findings suggest that MBL deficiency may manifest into DIC and organ failure during infectious diseases.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399528      PMCID: PMC2912947          DOI: 10.1016/j.imbio.2010.02.005

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  57 in total

1.  Mannan-binding lectin modulates the response to HSV-2 infection.

Authors:  M Gadjeva; S R Paludan; S Thiel; V Slavov; M Ruseva; K Eriksson; G-B Löwhagen; L Shi; K Takahashi; A Ezekowitz; J C Jensenius
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

2.  Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation.

Authors:  Cheng Hock Toh; John Samis; Colin Downey; John Walker; Lev Becker; Nicole Brufatto; Liliana Tejidor; Greg Jones; Wim Houdijk; Alan Giles; Marlys Koschinsky; Larry O Ticknor; Ray Paton; Richard Wenstone; Michael Nesheim
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 3.  Mannose-binding lectin and infection following allogeneic hemopoietic stem cell transplantation.

Authors:  Charles G Mullighan; Peter G Bardy
Journal:  Leuk Lymphoma       Date:  2004-02

Review 4.  Mannose-binding lectin deficiency--revisited.

Authors:  Peter Garred; Flemming Larsen; Hans O Madsen; Claus Koch
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

5.  Differential substrate and inhibitor profiles for human MASP-1 and MASP-2.

Authors:  Julia S Presanis; Krishnan Hajela; Géza Ambrus; Péter Gál; Robert B Sim
Journal:  Mol Immunol       Date:  2004-02       Impact factor: 4.407

6.  Ulex europaeus I lectin as a marker for vascular endothelium in human tissues.

Authors:  H Holthöfer; I Virtanen; A L Kariniemi; M Hormia; E Linder; A Miettinen
Journal:  Lab Invest       Date:  1982-07       Impact factor: 5.662

7.  Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients.

Authors:  Eve Y Smith; Linda A Charles; Elizabeth M Van Cott
Journal:  Am J Clin Pathol       Date:  2004-01       Impact factor: 2.493

Review 8.  Primitive complement system--recognition and activation.

Authors:  Teizo Fujita; Yuichi Endo; Masaru Nonaka
Journal:  Mol Immunol       Date:  2004-06       Impact factor: 4.407

9.  Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.

Authors:  Cheng Hock Toh; Lawrence O Ticknor; Colin Downey; Alan R Giles; Ray C Paton; Richard Wenstone
Journal:  Intensive Care Med       Date:  2002-11-22       Impact factor: 17.440

10.  Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus.

Authors:  Lei Shi; Kazue Takahashi; Joseph Dundee; Sarit Shahroor-Karni; Steffen Thiel; Jens Christian Jensenius; Faten Gad; Michael R Hamblin; Kedarnath N Sastry; R Alan B Ezekowitz
Journal:  J Exp Med       Date:  2004-05-17       Impact factor: 14.307

View more
  44 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

2.  Recombinant chimeric lectins consisting of mannose-binding lectin and L-ficolin are potent inhibitors of influenza A virus compared with mannose-binding lectin.

Authors:  Wei-Chuan Chang; Kevan L Hartshorn; Mitchell R White; Patience Moyo; Ian C Michelow; Henry Koziel; Bernard T Kinane; Emmett V Schmidt; Teizo Fujita; Kazue Takahashi
Journal:  Biochem Pharmacol       Date:  2010-10-28       Impact factor: 5.858

3.  Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis.

Authors:  Nirmal K Banda; Minoru Takahashi; Brandt Levitt; Magdalena Glogowska; Jessica Nicholas; Kazue Takahashi; Gregory L Stahl; Teizo Fujita; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

4.  Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica.

Authors:  Deyan Luo; Frank M Szaba; Lawrence W Kummer; Edward F Plow; Nigel Mackman; David Gailani; Stephen T Smiley
Journal:  J Immunol       Date:  2011-07-01       Impact factor: 5.422

5.  Polyphosphate suppresses complement via the terminal pathway.

Authors:  Jovian M Wat; Jonathan H Foley; Michael J Krisinger; Linnette Mae Ocariza; Victor Lei; Gregory A Wasney; Emilie Lameignere; Natalie C Strynadka; Stephanie A Smith; James H Morrissey; Edward M Conway
Journal:  Blood       Date:  2013-12-13       Impact factor: 22.113

Review 6.  Mannose-binding lectin and the balance between immune protection and complication.

Authors:  Kazue Takahashi
Journal:  Expert Rev Anti Infect Ther       Date:  2011-12       Impact factor: 5.091

7.  Mannose-binding lectin-associated serine protease-1 is a significant contributor to coagulation in a murine model of occlusive thrombosis.

Authors:  Laura R La Bonte; Vasile I Pavlov; Ying S Tan; Kazue Takahashi; Minoru Takahashi; Nirmal K Banda; Chenhui Zou; Teizo Fujita; Gregory L Stahl
Journal:  J Immunol       Date:  2011-12-12       Impact factor: 5.422

8.  Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis.

Authors:  Vasile I Pavlov; Mikkel-Ole Skjoedt; Ying Siow Tan; Anne Rosbjerg; Peter Garred; Gregory L Stahl
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

9.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

10.  An extracorporeal blood-cleansing device for sepsis therapy.

Authors:  Joo H Kang; Michael Super; Chong Wing Yung; Ryan M Cooper; Karel Domansky; Amanda R Graveline; Tadanori Mammoto; Julia B Berthet; Heather Tobin; Mark J Cartwright; Alexander L Watters; Martin Rottman; Anna Waterhouse; Akiko Mammoto; Nazita Gamini; Melissa J Rodas; Anxhela Kole; Amanda Jiang; Thomas M Valentin; Alexander Diaz; Kazue Takahashi; Donald E Ingber
Journal:  Nat Med       Date:  2014-09-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.